玻璃体切除术治疗糖尿病并发症:基于现代技术与设备的随机对照试验汇总分析
该汇总分析纳入同一机构五项随机临床试验中的943例增生性糖尿病视网膜病变相关并发症患者,均前瞻性接受小切口玻璃体切除术并联合抗血管内皮生长因子预处理,完成6个月随访;视力中位数从基线2.00改善至6个月1.00,95.5%患者视力改善或稳定,1.2%进展为无光感。
要点
- 943例患者6个月时视力中位数由基线2.00改善至1.00。
- 184例(19.5%)达到20/50或更好,652例(69.1%)达到20/200或更好。
- 术中并发症343例(36.4%),术后并发症199例(21.1%),最常见为玻璃体积血124例。
核心结论
- 小切口玻璃体切除术联合抗血管内皮生长因子预处理治疗增生性糖尿病视网膜病变相关并发症的临床结局,与采用小切口玻璃体切除术及抗血管内皮生长因子预处理之前的年代相比较为有利。
研究设计与样本
- 汇总分析,纳入同一机构开展的五项随机临床试验中的研究组与对照组受试者。
- 943例受试者前瞻性接受小切口玻璃体切除术并联合抗血管内皮生长因子预处理,治疗增生性糖尿病视网膜病变相关并发症,并完成6个月随访。
主要发现
- 研究人群视力从基线中位数2.00(四分位距1.3,2.3)改善至6个月中位数1.00(四分位距0.5,1.3)。
- 6个月时184例(19.5%)达到20/50或更好视力,652例(69.1%)达到20/200或更好视力。
- 901例(95.5%)视力改善或保持稳定,11例(1.2%)在6个月时发展为无光感。
- 术中并发症发生于343例(36.4%),199例(21.1%)发生术后并发症;最常见的术后并发症为玻璃体积血124例(占全部并发症的62.3%)。
- 86例(9.1%)需要非计划二次玻璃体切除术。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To report updated clinical outcomes in subjects undergoing pars plana vitrectomy (PPV) using modern techniques and equipment for the treatment of proliferative diabetic retinopathy-related complications. Pooled analysis of five randomized clinical trials conducted at the same institution and included both study and control subjects from the trials. METHODS: There were 943 subjects who prospectively underwent small-gauge PPV with antivascular endothelial growth factor pretreatment for proliferative diabetic retinopathy-related complications and completed 6-month follow-up. RESULTS: The visual acuity of the study population improved from median 2.00 (interquartile range 1.3, 2.3) at baseline to median 1.00 (interquartile range 0.5, 1.3) at 6 months. One hundred and eighty-four patients (19.5%) achieved 20/50 or better acuity, and 652 patients (69.1%) achieved 20/200 or better acuity at 6 months. The vision improved or remained stable in 901 patients (95.5%), and 11 patients (1.2%) developed no light perception at 6 months. Intraoperative complications occurred in 343 cases (36.4%), and 199 cases (21.1%) experienced a postoperative complication. The most common postoperative complication was vitreous hemorrhage in 124 cases (62.3% of all complications). Unplanned secondary PPV was necessary in 86 cases (9.1%). CONCLUSION: This study reports updated clinical outcomes in patients undergoing PPV for proliferative diabetic retinopathy-related complications which compares favorably with the age before small-gauge PPV and antivascular endothelial growth factor pretreatment.
引用
- Rush RB, Rush SW, Reinauer RM, et al. VITRECTOMY FOR DIABETIC COMPLICATIONS: A Pooled Analysis of Randomized Controlled Trials Using Modern Techniques and Equipment. Retina. 2022. PMID: 35263314. doi:10.1097/IAE.0000000000003471
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。